WO2021136333A1 - 一种制备3-位被酰胺基烷基取代的香豆素类化合物的方法及其产物和相关中间体 - Google Patents
一种制备3-位被酰胺基烷基取代的香豆素类化合物的方法及其产物和相关中间体 Download PDFInfo
- Publication number
- WO2021136333A1 WO2021136333A1 PCT/CN2020/141203 CN2020141203W WO2021136333A1 WO 2021136333 A1 WO2021136333 A1 WO 2021136333A1 CN 2020141203 W CN2020141203 W CN 2020141203W WO 2021136333 A1 WO2021136333 A1 WO 2021136333A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- group
- formula
- tumors
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 69
- -1 coumarin compound Chemical class 0.000 title claims abstract description 35
- 239000000543 intermediate Substances 0.000 title abstract description 52
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 title abstract description 5
- 229960000956 coumarin Drugs 0.000 title abstract description 4
- 235000001671 coumarin Nutrition 0.000 title abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 131
- 150000001875 compounds Chemical class 0.000 claims abstract description 116
- 150000002367 halogens Chemical class 0.000 claims abstract description 46
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 45
- 239000001257 hydrogen Substances 0.000 claims abstract description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 23
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract description 10
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 239000002904 solvent Substances 0.000 claims description 69
- 239000013078 crystal Substances 0.000 claims description 65
- 238000006243 chemical reaction Methods 0.000 claims description 64
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 57
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 42
- 125000000623 heterocyclic group Chemical group 0.000 claims description 40
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 28
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 125000005842 heteroatom Chemical group 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 23
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 238000002411 thermogravimetry Methods 0.000 claims description 18
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 15
- 230000004906 unfolded protein response Effects 0.000 claims description 15
- 150000001408 amides Chemical class 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 14
- 230000009385 viral infection Effects 0.000 claims description 14
- 239000004215 Carbon black (E152) Substances 0.000 claims description 13
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 13
- 229930195733 hydrocarbon Natural products 0.000 claims description 13
- 150000002430 hydrocarbons Chemical group 0.000 claims description 13
- 238000001179 sorption measurement Methods 0.000 claims description 13
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 12
- 150000002825 nitriles Chemical class 0.000 claims description 12
- 208000036142 Viral infection Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 11
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 238000001228 spectrum Methods 0.000 claims description 8
- 239000012043 crude product Substances 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 6
- 102100030013 Endoribonuclease Human genes 0.000 claims description 6
- 101001010783 Homo sapiens Endoribonuclease Proteins 0.000 claims description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 239000008096 xylene Substances 0.000 claims description 6
- ACRWYXSKEHUQDB-UHFFFAOYSA-N 3-phenylpropionitrile Chemical compound N#CCCC1=CC=CC=C1 ACRWYXSKEHUQDB-UHFFFAOYSA-N 0.000 claims description 5
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 5
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 claims description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 238000006482 condensation reaction Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000003759 ester based solvent Substances 0.000 claims description 5
- 239000004210 ether based solvent Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 5
- 229940011051 isopropyl acetate Drugs 0.000 claims description 5
- 229910052987 metal hydride Inorganic materials 0.000 claims description 5
- 150000004681 metal hydrides Chemical class 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 239000000010 aprotic solvent Substances 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 229940125904 compound 1 Drugs 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 4
- 150000007529 inorganic bases Chemical class 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- 238000012261 overproduction Methods 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- 241000710831 Flavivirus Species 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 201000011152 Pemphigus Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims description 3
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims description 2
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 208000002017 Autoimmune Hypophysitis Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 2
- 241001115402 Ebolavirus Species 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 2
- 206010021263 IgA nephropathy Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000002774 Paraproteinemias Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 241000710886 West Nile virus Species 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 206010003230 arteritis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 208000025402 neoplasm of esophagus Diseases 0.000 claims description 2
- 210000000944 nerve tissue Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 208000011610 primary hypophysitis Diseases 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 208000023958 prostate neoplasm Diseases 0.000 claims description 2
- 230000003362 replicative effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 208000014680 small intestine neoplasm Diseases 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 208000025444 tumor of salivary gland Diseases 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 125000005587 carbonate group Chemical group 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- HJBAHMQOPDWMJM-UHFFFAOYSA-N ethyl 2-acetyl-4-morpholin-4-yl-4-oxobutanoate Chemical compound CCOC(=O)C(CC(=O)N1CCOCC1)C(=O)C HJBAHMQOPDWMJM-UHFFFAOYSA-N 0.000 description 23
- 238000004128 high performance liquid chromatography Methods 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- IFDGMRMUJYGWQQ-UHFFFAOYSA-N 7-hydroxy-6-methoxy-4-methyl-3-(2-morpholin-4-yl-2-oxoethyl)-2-oxochromene-8-carbaldehyde Chemical compound O=C1OC=2C(C=O)=C(O)C(OC)=CC=2C(C)=C1CC(=O)N1CCOCC1 IFDGMRMUJYGWQQ-UHFFFAOYSA-N 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 238000001514 detection method Methods 0.000 description 14
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical group C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 13
- LLLQAMNGYJQUKK-UHFFFAOYSA-N 2-bromo-1-morpholin-4-ylethanone Chemical compound BrCC(=O)N1CCOCC1 LLLQAMNGYJQUKK-UHFFFAOYSA-N 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 238000009826 distribution Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 150000001335 aliphatic alkanes Chemical class 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 7
- 239000004312 hexamethylene tetramine Substances 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 238000013112 stability test Methods 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000003368 amide group Chemical group 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 150000004775 coumarins Chemical class 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 0 CC(c(c(O1)c2)c(*)c(*)c2O)=C(*)C1=O Chemical compound CC(c(c(O1)c2)c(*)c(*)c2O)=C(*)C1=O 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000022244 formylation Effects 0.000 description 4
- 238000006170 formylation reaction Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960001701 chloroform Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- CFXQEHVMCRXUSD-UHFFFAOYSA-N 1,2,3-Trichloropropane Chemical compound ClCC(Cl)CCl CFXQEHVMCRXUSD-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- GPJJASIJVRXZFI-UHFFFAOYSA-N 4-methoxybenzene-1,3-diol Chemical compound COC1=CC=C(O)C=C1O GPJJASIJVRXZFI-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- PGMYKACGEOXYJE-UHFFFAOYSA-N pentyl acetate Chemical compound CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- YMQRPXBBBOXHNZ-UHFFFAOYSA-N 2-chloro-1-morpholin-4-ylethanone Chemical compound ClCC(=O)N1CCOCC1 YMQRPXBBBOXHNZ-UHFFFAOYSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- BATGDOSJDGVCBF-UHFFFAOYSA-N C(CC(=O)C)(=O)OCCCC(=O)N(C)C Chemical group C(CC(=O)C)(=O)OCCCC(=O)N(C)C BATGDOSJDGVCBF-UHFFFAOYSA-N 0.000 description 1
- 101100219382 Caenorhabditis elegans cah-2 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 101100114697 Danio rerio cpeb1 gene Proteins 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000005257 alkyl acyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N but-2-ene Chemical group CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 229940043232 butyl acetate Drugs 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical group 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical class N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical group [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- LMUMMJCCZMWLEN-UHFFFAOYSA-N spiro[3.3]heptyl Chemical group [CH]1CCC11CCC1 LMUMMJCCZMWLEN-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000010512 thermal transition Effects 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to the field of medicinal chemistry, and in particular to a method for preparing coumarin compounds whose 3-position is substituted by an amidoalkyl group, and products and related intermediates thereof.
- Inositol enzyme 1 ⁇ is an endonuclease, which is mainly located in the endoplasmic reticulum connected to the nucleus. It regulates gene expression by exerting the catalytic function of endonuclease, thereby affecting the endoplasmic reticulum. Processing and modification of unfolded proteins.
- IRE-1 ⁇ an important part of the signaling pathway of this mechanism, will be activated and removed
- UTR unfolded protein response
- a specific base sequence on the target mRNA regulates the expression of related genes, thereby enhancing protein folding and modification, alleviating the stress of the endoplasmic reticulum, repairing the imbalance of the internal environment of the cell, and promoting cell survival. Therefore, the function of IRE-1 ⁇ is closely related to diseases in many fields such as tumor, metabolism, immunity, viral infection, and cardiovascular.
- tumor cells for cancer, the rapid proliferation of malignant tumor cells has caused tumor cells to be generally in an out-of-control state due to the interaction of various factors such as hypoxia, insufficient nutrient supply, metabolic disorders, and carcinogenic pressure.
- various factors such as hypoxia, insufficient nutrient supply, metabolic disorders, and carcinogenic pressure.
- Such tumor microenvironment continues to affect the internal Plasma reticulum folding; in addition, chemotherapy, biological therapy, and radiation therapy can also cause endoplasmic reticulum stress response and fight apoptosis through UPR. Therefore, IRE-1 ⁇ in tumor cells is continuously and extensively activated under long-term stress, making it It becomes an ideal tumor target that can be acted by drugs (such as IRE-1 ⁇ inhibitors).
- CN103079558 A discloses a class of small molecule compounds that use a coumarin structure as the core and can inhibit IRE-1 ⁇ , in which compounds with the following specific structures are provided. This is a potent, low-toxic, highly selective IRE-1 ⁇ inhibitor
- CN107973784 A discloses the following synthetic route of an ethyl acetoacetate compound (2-(N,N-dimethylaminocarbonylmethyl)ethyl acetoacetate) substituted by an amidoalkyl group at the ⁇ -position:
- the 1,3-dicarbonyl group in the ethyl acetoacetate structure of this compound undergoes condensation reaction with iminoamide derivatives under alkaline conditions and is used to synthesize pyrimidine compounds
- the first aspect of the present invention provides a method for preparing a compound of formula (VII), comprising
- R 1 and R 2 are each independently selected from hydrogen, halogen and -O (C 1-8 alkyl), wherein the alkyl is optionally substituted with 1 or 2 groups selected from the group consisting of halogen, C 1-8 alkyl group substituted by 1-2 hydroxy groups, -O (C 1-8 alkyl group);
- R 3 is -LC(O)NR 5 R 6 , and L is C 1-3 alkylene;
- R 4 is -O(C 1-6 alkyl
- R 5 and R 6 are each independently selected from hydrogen, -O (C 1-8 alkyl), C 3-10 cyclic hydrocarbon group, wherein the alkyl group and cyclic hydrocarbon group are optionally 1 or 2 selected from the following Group substitution: halogen, -O (C 1-8 alkyl), -NH 2 , -NH (C 1-8 alkyl), -N (C 1-8 alkyl) 2 , five- to seven-membered hetero Cyclic group, wherein the heterocyclic group contains 1-2 heteroatoms selected from N, O, S, and the heterocyclic group is optionally composed of 1-2 groups selected from C 1-8 alkyl Replace; or
- R 5 and R 6 together with the N atom to which they are connected form a five- to seven-membered heterocyclic group, which optionally contains an additional heteroatom selected from N, O, S, and optionally Substituted by 1 or 2 groups selected from: halogen, C 1-8 alkyl, -O (C 1-8 alkyl) , -NH 2 , -NH (C 1-8 alkyl), -N (C 1-8 alkyl) 2 .
- the second aspect of the present invention provides a method for preparing a compound of formula (I), which includes the step (A) described in the first aspect of the present invention and the following step (B):
- R 1 , R 2 and R 3 are as defined in the first aspect of the present invention.
- the third aspect of the present invention provides an intermediate compound, the structure of which is shown in the following formula (V):
- R 3 and R 4 are as defined in the first aspect of the present invention.
- the crystal form I of compound Orin1001 is provided, wherein the X-ray powder diffraction pattern of the crystal form I is about 8.44 ⁇ 0.2°, 13.11 ⁇ 0.2°, 15.70 ⁇ 0.2°, 19.73 ⁇ 0.2°, There are characteristic peaks at the diffraction angles (2 ⁇ ) of 21.00 ⁇ 0.2° and 22.91 ⁇ 0.2°,
- the present invention provides a pharmaceutical composition comprising the crystal form I of the present invention and one or more pharmaceutically acceptable carriers.
- the present invention also provides the crystalline form I of the present invention or the pharmaceutical composition of the present invention when preparing to treat or prevent diseases, disorders or conditions related to unfolded protein response (UPR), or when preparing to treat or prevent
- URR unfolded protein response
- RIDD IRE1-dependent decay
- Figure 1 shows the X-ray powder diffraction (XRPD) pattern of Form I.
- FIG. 1 shows the thermogravimetric analysis (TGA) spectrum of Form I.
- FIG. 3 shows the differential scanning calorimetry (DSC) spectrum of Form I.
- Figure 4 shows the dynamic moisture adsorption (DVS) spectrum of Form I.
- Fig. 5 shows the XRPD comparison chart of Form I before and after DVS detection.
- Fig. 6 shows the result of stability test of Form I (XRPD)-Day 7, where "-1" and "-2" at the end of the annotation of the curve represent “Sample-1” and “Sample-2", respectively.
- Fig. 7 shows the result of stability test of crystal form I (XRPD)-day 14, where "-1" and “-2" at the end of the annotation of the curve represent “Sample-1” and “Sample-2", respectively.
- Fig. 8 shows the particle size distribution test chart of crystal form I.
- Figure 9 shows the test results (XRPD) of Form I after mechanical treatment.
- substituted and “substituted” mean that one or more (for example, one, two, three, or four) hydrogens on the designated atom are replaced by a selection from the indicated group, provided that it does not exceed the specified amount.
- the specified atom has the normal valence in the current situation and the substitution forms a stable compound. Combinations of substituents and/or variables are only permissible when such combinations form stable compounds.
- the position of the substituent may be one or more hydrogen atoms, provided that the structure formed can make the compound reach a stable state.
- the point of attachment of a substituent can be from any suitable position of the substituent.
- one or more or “at least one” can mean one, two, three, four, five, six, seven, eight, nine or more (A).
- mn used herein refers to the range of m to n and the sub-range composed of each point value therein and each point value.
- C 1-8 covers the range of 1-8 carbon atoms, and should be understood to also cover any sub-range therein and each point value, such as C 2-5 , C 3-4 , C 1- 2.
- C 3-10 should also be understood in a similar manner, for example, it can cover any sub-range and point value contained therein, such as C 3-9 , C 6-9 , C 6-8 , C 6- 7. C 7-10 , C 7-9 , C 7-8 , C 8-9, etc. and C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 and so on.
- the expression "three yuan to ten yuan” should be understood as covering any sub-range and each point value, such as 3-5 yuan, 3-6 yuan, 3-7 yuan, 3-8 yuan, 4-5 Yuan, 4-6 yuan, 4-7 yuan, 4-8 yuan, 5-7 yuan, 5-8 yuan, 6-7 yuan, 7-8 yuan, 9-10 yuan, etc., and 3, 4, 5, 6, 7, 8, 9, 10 yuan, etc.
- Other similar expressions in this article should also be understood in a similar way.
- halogen or halogen or “halo” should be understood to mean a fluorine (F), chlorine (Cl), bromine (Br) or iodine (I) atom, preferably a fluorine, chlorine or bromine atom.
- alkyl refers to a saturated linear, branched or cyclic hydrocarbon group.
- C 1-8 alkyl refers to a saturated linear, branched or saturated chain having 1-8 (for example, 1, 2, 3, 4, 5, 6, 7 or 8) carbon atoms Cyclic hydrocarbon group.
- C 1-6 alkyl can be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, new Pentyl, 3-methylpentan-3-yl, hexyl (e.g., n-hexyl, cyclohexyl, etc.).
- the "C 1-8 alkyl group” covers the sub-range therein, such as “C 1-3 alkyl group", “C 2-3 alkyl group", “C 4-6 alkyl group” and the like.
- alkylene when used alone or in combination with other groups herein, refers to a saturated linear or branched divalent hydrocarbon group.
- C 1-8 alkylene refers to an alkylene group having 1-8 carbon atoms, such as methylene, ethylene, propylene, butylene, 1-methylethylene, 2 -Methyl ethylene or methyl propylene, etc.
- alkoxy refers to an alkyl group as defined above connected to an oxygen atom by a single bond. The alkoxy group is connected to the rest of the molecule through an oxygen atom.
- the alkoxy group can be represented as -O (alkyl).
- C 1-8 alkoxy or “-O (C 1-8 alkyl)” refers to an alkoxy group containing 1-8 carbon atoms, in which the alkyl part can be linear, branched or cyclic ⁇ Like structure.
- Alkoxy includes, but is not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, n-pentoxy, cyclopentyloxy, cyclohexyloxy and the like.
- cyclic hydrocarbon group refers to a saturated or unsaturated non-aromatic cyclic hydrocarbon group composed of carbon atoms and hydrogen atoms, and preferably contains 1 or 2 rings.
- the cyclic hydrocarbon group may be a monocyclic ring, a fused polycyclic ring, a bridged ring or a spiro ring structure.
- the cyclic hydrocarbon group may have 3-10 carbon atoms, that is, "C 3-10 cyclic hydrocarbon group", such as C 3-8 cyclic hydrocarbon group, C 5 cyclic hydrocarbon group, C 6 cyclic hydrocarbon group, C 7 cyclic hydrocarbon group.
- Non-limiting examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1]heptyl, spiro[3.3]heptyl, and the like.
- heterocyclic group or “heterocyclic hydrocarbon group” means having, for example, 3-10 (suitably 3-8, more suitably 3-7, 5-7, especially 4-6)
- a monocyclic or bicyclic non-aromatic ring system of ring atoms three-membered to ten-membered, three-membered to eight-membered, three-membered to six-membered), wherein at least one ring atom (for example, 1, 2, or 3) is selected from N , O and S heteroatoms, and the remaining ring atoms are C.
- the ring system can be saturated (also can be understood as the corresponding "heterocycloalkyl”) or unsaturated (that is, having one or more double bonds and/or triple bonds in the ring).
- the heterocyclic group may be, for example, a 4-membered ring, such as azetidinyl, oxetanyl, or a 5-membered ring, such as tetrahydrofuranyl, dioxanyl, pyrrolidinyl, imidazolidinyl, pyridine Oxazolidinyl, pyrrolinyl, oxopyrrolidinyl, 2-oxoimidazolidine-1-yl; or 6-membered ring, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl , Thiomorpholinyl, piperazinyl, 1,1-dioxo-1,2-thiazin-2-yl or trithiazyl; or 7-membered ring, such as diazayl ring.
- a 4-membered ring such as azetidinyl, oxetanyl, or a 5-membere
- the heterocyclic group may be benzo-fused.
- the heterocyclic group can be bicyclic without limitation, for example a 5,5-membered ring, such as hexahydrocyclopentane[c]pyrrole-2(1H)-yl) ring; or a 5,6-membered bicyclic ring, such as Hexahydropyrrolo[1,2-a]pyrazine-2(1H)-yl ring.
- the ring containing the nitrogen atom may be partially unsaturated, that is, it may contain one or more double bonds without limitation, such as 2,5-dihydro-1H-pyrrolyl, 4H- [1,3,4]thiadiazinyl, 4,5-dihydrooxazolyl or 4H-[1,4]thiazinyl ring, or it may be benzo-fused without limitation, for example Dihydroisoquinolinyl ring.
- hydrocarbon solvent refers to a solvent of linear, branched or cyclic hydrocarbon having 1-10 carbon atoms.
- the hydrocarbon can be saturated or unsaturated.
- hydrocarbon solvents include, for example, alkane solvents, including but not limited to n-pentane, n-hexane, cyclohexane, n-heptane, octane or a combination thereof, preferably hexane or heptane.
- hydrocarbon solvents also include aromatic hydrocarbon solvents, which contain at least one aromatic ring and are optionally substituted with linear, branched, or cyclic hydrocarbon groups.
- Aromatic solvents include but are not limited to benzene, toluene, xylene or a combination thereof, preferably toluene, xylene or a combination thereof.
- halogenated alkanes solvent refers to the alkane solvents mentioned above, of which one or more (e.g. 1-6, 1-5, 1-4, 1-3, or 1-2 A) The hydrogen atom is replaced by a halogen.
- the halogens may be the same or different, and may be located on the same or different C atoms.
- Halogenated alkane solvents include, but are not limited to, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, hexachloroethane and 1,2,3-trichloropropane or a combination thereof, preferably two Chloroform, trichloromethane, 1,2-dichloroethane or a combination thereof, especially dichloromethane.
- ester solvent refers to solvents of esters having 3-10 carbon atoms. Ester solvents include, but are not limited to, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, pentyl acetate or a combination thereof, preferably ethyl acetate, isopropyl acetate, butyl acetate or a combination thereof.
- ether-based solvent refers to an ether solvent having 2-10 carbon atoms.
- ether solvents include, but are not limited to, diethyl ether, isopropyl ether, tetrahydrofuran, methyltetrahydrofuran, dioxane, ethylene glycol dimethyl ether, methyl tert-butyl ether or a combination thereof, preferably tetrahydrofuran, methyltetrahydrofuran, Dioxane, ethylene glycol dimethyl ether, methyl tert-butyl ether, or a combination thereof.
- nitrile solvent refers to a solvent of nitriles having 2-10 carbon atoms.
- nitrile solvents include, but are not limited to, acetonitrile, propionitrile, butyronitrile, benzonitrile, benzylacetonitrile or a combination thereof, preferably acetonitrile, benzonitrile, benzylacetonitrile or a combination thereof, especially acetonitrile.
- disubstituted amide solvent refers to an amide solvent: an amide formed by linking a C 1-3 alkyl acyl group with an amine compound, in which two amide N atoms are independently selected from the C 1-3 alkyl group. Alkyl substitution, or the two substituents on the amide N atom together with the amide N atom to which it is connected form a five- to seven-membered heterocyclic ring containing one N atom.
- disubstituted amide solvents include, but are not limited to, N,N-dimethylformamide, N,N-diethylformamide, N,N-dimethylacetamide, N,N-diethylacetamide, N-methylpyrrolidone or a combination thereof.
- room temperature refers to about 20-30°C, preferably about 25°C.
- the percentages, parts, etc. herein are all by weight. Unless otherwise stated, the concentration is calculated by weight, the liquid ratio in the mixed solution is calculated by volume, and the ratio (including percentage) of the reaction reagent to the compound and the reaction yield are calculated by mole.
- crystalline form or "crystalline” refers to any solid substance exhibiting a three-dimensional order, as opposed to an amorphous solid substance, which produces a characteristic X-ray powder diffraction pattern with well-defined peaks.
- X-ray powder diffraction (XRPD) pattern refers to an experimentally observed diffraction pattern or a parameter, data or value derived therefrom.
- the XRPD pattern is usually characterized by peak position (abscissa) and/or peak intensity (ordinate).
- the XRPD pattern can be measured on an instrument of Bruker D8advance X, for example.
- the term "2 ⁇ " refers to the peak position expressed in degrees (°) based on the setting in the X-ray diffraction experiment, and is usually the unit of abscissa in the diffraction pattern. If the incident beam forms an angle ⁇ with a certain lattice plane, the reflection is diffracted, and the experimental setup needs to record the reflected beam at an angle of 2 ⁇ . It should be understood that the specific 2 ⁇ value of the specific crystal form mentioned herein is intended to mean the 2 ⁇ value (expressed in degrees) measured using the X-ray diffraction experimental conditions described herein.
- the term "substantially" for X-ray diffraction peaks means that the representative peak position and intensity change are taken into account. There may be differences in the XRPD patterns between the results obtained by measuring the same polymorphs for a variety of reasons.
- the sources of errors include differences in sample preparation (such as sample height), instrument errors, scale errors, and operational errors (including errors in determining peak positions).
- Preferential orientation that is, the lack of random orientation in the crystals of XRPD samples, may result in significant differences in relative peak heights. Scale errors and sample height errors usually cause all peaks in the diffraction pattern to be shifted by the same amount in the same direction.
- the same method can be used to make up for the differences between the diffractometers, so that the XRPD peak positions obtained by the two different instruments are consistent.
- the peak positions of a particular polymorph usually differ by about ⁇ 0.2° (2 ⁇ ).
- the relative peak intensity will also vary due to differences between instruments and the degree of crystallinity, preferred orientation, prepared sample surface, and other factors known to those skilled in the art, and should be considered. This is only a qualitative measurement.
- DSC Differential scanning calorimetry
- TGA Thermogravimetric analysis
- Dynamic moisture adsorption is a common method to investigate the moisture adsorption of drugs, excipients or packaging materials through a dynamically accelerated moisture adsorption process.
- the moisture adsorption isotherm is usually used to describe the correlation between sample moisture content and relative humidity in the process of sample moisture adsorption.
- the DVS profile can be measured, for example, on an instrument of model IGASorp.
- particle size distribution refers to the range of particle size distribution, which can be expressed by the particle size corresponding to the cumulative particle size distribution ratio (expressed as a fraction, decimal, or percentage) reaching a specific value, such as D(0.5) Or D50 represents the median particle size.
- the particle size distribution can be measured by a laser light diffraction method, for example, can be measured by a Mastersizer laser particle size analyzer manufactured by Malvern, USA.
- atomic economy means that in the chemical synthesis process, the synthesis method and process are designed to convert as many atoms of the raw material used in the reaction process as possible into the product molecule.
- a reaction or synthesis route with high atom economy can increase efficiency and reduce the generation of by-products or waste.
- pharmaceutically acceptable means that it is compatible with other components in the formulation and has no unacceptable toxicity to the subject and the user.
- “Pharmaceutically acceptable carrier” refers to those carrier materials that have no obvious stimulating effect on organisms and do not impair the biological activity and performance of the active compound. “Pharmaceutically acceptable carriers” include but are not limited to glidants, sweeteners, diluents, preservatives, dyes/colorants, flavors, surfactants, wetting agents, dispersants, disintegrants, Stabilizer, solvent or emulsifier.
- administration refers to a method that enables the compound or composition to be delivered to a desired site of biological action. These methods include, but are not limited to, parenteral (including intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular injection or infusion), topical, rectal administration and the like.
- the term "effective amount” refers to the amount of the active ingredient that will achieve the desired effect to a certain extent after administration, such as one that relieves the condition being treated Species or multiple symptoms or to prevent the occurrence of a disease or its symptoms.
- “Individual” as used herein includes human or non-human animals, especially humans.
- the first aspect of the present invention provides a method for preparing a compound of formula (VII), comprising
- R 1 and R 2 are each independently selected from hydrogen, halogen and -O (C 1-8 alkyl), wherein the alkyl is optionally substituted with 1 or 2 groups selected from the group consisting of halogen, C 1-8 alkyl group substituted by 1-2 hydroxy groups, -O (C 1-8 alkyl group);
- R 3 is -LC(O)NR 5 R 6 , and L is C 1-3 alkylene;
- R 4 is -O(C 1-6 alkyl
- R 5 and R 6 are each independently selected from hydrogen, -O (C 1-8 alkyl), C 3-10 cyclic hydrocarbon group, wherein the alkyl group and cyclic hydrocarbon group are optionally 1 or 2 selected from the following Group substitution: halogen, -O (C 1-8 alkyl), -NH 2 , -NH (C 1-8 alkyl), -N (C 1-8 alkyl) 2 , five- to seven-membered hetero Cyclic group, wherein the heterocyclic group contains 1-2 heteroatoms selected from N, O, S, and the heterocyclic group is optionally composed of 1-2 groups selected from C 1-8 alkyl Replace; or
- R 5 and R 6 together with the N atom to which they are connected form a five- to seven-membered heterocyclic group, which optionally contains an additional heteroatom selected from N, O, S, and optionally Substituted by 1 or 2 groups selected from: halogen, C 1-8 alkyl, -O (C 1-8 alkyl) , -NH 2 , -NH (C 1-8 alkyl), -N (C 1-8 alkyl) 2 .
- R 1 and R 2 are each independently selected from hydrogen, halogen, and -O (C 1-4 alkyl), wherein the alkyl group is optionally substituted by 1 or 2 groups selected from Substitution: halogen, -O (C 1-4 alkyl).
- R 1 and R 2 are each independently selected from hydrogen, halogen, and -O(C 1-2 alkyl), wherein the alkyl group is optionally substituted by halogen or methoxy.
- R 1 and R 2 are each independently hydrogen, methoxy or
- R 4 is -O (C 1-4 alkyl), preferably -O (C 1-3 alkyl). In a more preferred embodiment, R 4 is -O(C 1-2 alkyl). In a particular embodiment, R 4 is ethoxy.
- L is methylene or ethylene. In a preferred embodiment, L is methylene.
- R 5 and R 6 are each independently selected from hydrogen, C 1-6 alkyl, wherein the alkyl is optionally substituted with 1-2 groups selected from the group consisting of halogen, -O (C 1-6 alkyl), -NH 2 , -NH (C 1-6 alkyl), -N (C 1-6 alkyl) 2 , five- to seven-membered heterocyclic group, wherein the heterocyclic ring
- the group contains 1-2 heteroatoms selected from N, O, S, and the heterocyclic group is optionally substituted with 1-2 groups selected from C 1-6 alkyl; or
- R 5 and R 6 together with the N atom to which they are connected form a five- to seven-membered heterocyclic group, which optionally contains an additional heteroatom selected from N, O, S, and optionally Substituted by 1-2 groups selected from: halogen, C 1-6 alkyl, -O (C 1-6 alkyl) , -NH 2 , -NH (C 1-6 alkyl), -N (C 1-6 alkyl) 2 .
- R 5 and R 6 are each independently selected from hydrogen, C 1-4 alkyl, wherein said alkyl is optionally substituted with 1-2 groups selected from the group consisting of halogen, -O (C 1-2 alkyl), -NH (C 1-2 alkyl), -N (C 1-2 alkyl) 2 , five- to seven-membered heterocyclic group, wherein the heterocyclic group contains 1-2 heteroatoms selected from N, O, S, and at least one of the heteroatoms is N, and the heterocyclic group is optionally substituted with 1-2 heteroatoms selected from C 1-4 alkyl Group substitution; or
- R 5 and R 6 together with the N atom to which they are connected form a five- to seven-membered heterocyclic group, which optionally contains an additional heteroatom selected from N, O, S, and optionally Substituted by 1-2 groups selected from the group consisting of halogen, C 1-4 alkyl, -O (C 1-2 alkyl), -NH (C 1-2 alkyl), -N (C 1- 2 alkyl) 2.
- R 5 and R 6 are each independently selected from hydrogen, C 1-2 alkyl, wherein said alkyl is optionally substituted with 1-2 groups selected from the following: methyl Oxy, dimethylamino, morpholinyl, piperidinyl or piperazinyl, said morpholinyl, piperidinyl or piperazinyl is optionally substituted by methyl; or
- R 5 and R 6 together with the N atom to which they are attached form a morpholinyl, piperidinyl or piperazinyl group, which is optionally substituted by methyl.
- R 5 and R 6 are each independently selected from hydrogen, C 1-2 alkyl, wherein said alkyl is substituted by morpholino; or
- R 5 and R 6 together with the N atom to which they are attached form a morpholinyl group.
- the compound of formula (VII) has the structure of compound 5A2, and step (A) is as follows: react compound 1 with compound B1 to prepare compound 5A2
- step (A) is carried out under acidic conditions.
- the reaction temperature is -20°C to 70°C.
- the reaction temperature is -5°C to 60°C.
- the reaction temperature is 20°C to 50°C.
- the second aspect of the present invention provides a method for preparing a compound of formula (I), which includes the step (A) described in the first aspect of the present invention and the following step (B):
- R 1 , R 2 and R 3 are as defined in the first aspect of the present invention.
- the formylation reagent is selected from hexamethylenetetramine and paraformaldehyde.
- step (B) is carried out in the presence of an acid.
- the reaction temperature is 50°C to 120°C, preferably 60°C to 100°C, more preferably 80°C to 90°C.
- the compound of formula (I), the reaction product of step (A), is purified as follows:
- Step i mixing the crude compound of formula (I) with a halogenated alkane solvent and water to obtain a mixture.
- Step ii Separate the organic phase of the mixture obtained in Step i, concentrate to obtain a solid, and wash the solid with a suitable solvent to obtain a crystalline compound of formula (I).
- a step of washing the mixture is further included between step i and step ii.
- an alkaline aqueous solution is used to wash the mixture.
- step i and step ii a step of adjusting the pH value of the mixture is further included, wherein the pH value of the mixture is adjusted to be close to neutral.
- the pH is adjusted to about 6 to 8, preferably about 7.
- step ii after separating the organic phase in step ii and before concentrating, it further includes a step of filtration or centrifugation, and the solution obtained by filtration or centrifugation is concentrated to obtain a solid.
- the step of filtering or centrifuging is filtering.
- a drying step is further included to substantially remove or partially remove the moisture in the organic phase.
- the suitable solvent described in step ii is an organic solvent.
- the organic solvent is selected from nitrile solvents, ester solvents, and combinations thereof, preferably nitrile solvents or ester solvents.
- the nitrile solvent is selected from acetonitrile, benzonitrile, benzylacetonitrile or a combination thereof, preferably acetonitrile.
- the ester solvent is selected from ethyl acetate, isopropyl acetate, butyl acetate or a combination thereof, preferably ethyl acetate.
- the crude compound of formula (I) in step i refers to the residue obtained by concentrating the reaction mixture under reduced pressure to remove the solvent therein after the reaction in step (A) is completed.
- the crude compound of formula (I) in step i means that after the reaction in step (A) is completed, the residue obtained by concentrating the reaction mixture under reduced pressure is dissolved in a solvent, and a short pad of silica gel ) After filtration, the residue obtained by concentrating the filtrate.
- step (B) intermediate compound of formula (VII) reacts with formylation reagent to obtain compound of formula (I), it is purified according to a method including the following steps:
- Step i Concentrate the reaction solution, add water and a seed crystal of the compound of formula (I) to induce crystallization;
- Step ii Separate the crude product obtained in Step i, stir with a suitable solvent under heating, and then lower the temperature to obtain a crystalline compound of formula (I).
- step ii after separating the crude product in step ii and before stirring with a suitable solvent under heating, the step of rinsing the crude product with a suitable solvent is further included.
- step ii is separated to obtain the crystalline compound of formula (I), it further includes the steps of rinsing with a suitable solvent and drying.
- the suitable solvent in step ii is selected from a nitrile solvent or a mixed solvent of a nitrile solvent and water.
- the nitrile solvent is selected from acetonitrile, benzonitrile, benzylacetonitrile or a combination thereof, preferably acetonitrile.
- the heating temperature in step ii is preferably 40-80°C, more preferably 50-70°C.
- the heating time of step ii is at least 2 hours, preferably at least 4 hours, and more preferably at least 8 hours.
- the compound of formula (I) has the structure of compound Orin1001, and step (A) is as follows: react compound 5A2 with a formylation reagent to prepare compound Orin1001
- the method of the present invention further includes the following steps (a) and (b) before step (A).
- X is halogen; L, R 3 , R 5 and R 6 are as defined above.
- the reaction is carried out in an organic solvent.
- the organic solvent is a neutral aprotic solvent.
- the organic solvent is selected from hydrocarbon solvents, halogenated hydrocarbon solvents, ether solvents, disubstituted amide solvents, ester solvents, and combinations thereof.
- the hydrocarbon solvent is selected from toluene, xylene, and combinations thereof.
- the halogenated hydrocarbon solvent is dichloromethane.
- the ether solvent is selected from tetrahydrofuran, methyltetrahydrofuran, dioxane, ethylene glycol dimethyl ether, methyl tert-butyl ether, and combinations thereof.
- the disubstituted amide solvent is selected from N,N-dimethylformamide, N,N-diethylformamide, N,N-dimethylacetamide, N,N- Diethylacetamide, N-methylpyrrolidone and combinations thereof.
- the ester solvent is selected from ethyl acetate, isopropyl acetate, butyl acetate, and combinations thereof.
- the reaction temperature is -10°C to 60°C, preferably 0°C to room temperature, more preferably 0°C to 10°C.
- X is halogen; R 3 and R 4 are as defined above.
- the reaction is carried out in the presence of a base, which is an organic base or an inorganic base.
- the organic base is selected from NaNH 2 , sodium alkoxide, K-HMDS, Li-HMDS.
- the inorganic base is selected from carbonates and metal hydrides.
- the carbonate is selected from sodium carbonate, potassium carbonate, lithium carbonate; preferably sodium carbonate or potassium carbonate.
- the carbonate is potassium carbonate.
- the metal hydride is selected from NaH, KH, LiH, CaH 2 . In a particular embodiment, the metal hydride is NaH.
- the reaction is carried out in an organic solvent.
- the organic solvent is a neutral aprotic solvent.
- the organic solvent is selected from hydrocarbon solvents, halogenated hydrocarbon solvents, ether solvents, disubstituted amide solvents, and combinations thereof.
- the hydrocarbon solvent is selected from toluene, xylene, and combinations thereof.
- the halogenated hydrocarbon solvent is dichloromethane.
- the ether solvent is selected from tetrahydrofuran, methyltetrahydrofuran, dioxane, ethylene glycol dimethyl ether, methyl tert-butyl ether, and combinations thereof.
- the disubstituted amide solvent is selected from N,N-dimethylformamide, N,N-diethylformamide, N,N-dimethylacetamide, N,N- Diethylacetamide, N-methylpyrrolidone and combinations thereof.
- the reaction temperature is -20 to 100°C, preferably -20 to 80°C, more preferably -10 to 60°C.
- step (a) is as follows:
- the compound of formula (III) has the structure of compound C1
- the compound of formula (IV) is ethyl acetoacetate
- the compound of formula (V) has the structure of compound B1 as follows
- Step (b) is as follows:
- X in step (a) or step (b) is selected from Cl and Br. In a preferred embodiment, X is Br.
- the method of the first aspect of the invention is implemented through the following route:
- step (a), step (b) and step (A) are as defined above.
- the method of the second aspect of the invention is implemented through the following route:
- step (a), step (b), step (A) and step (B) are as described above definition.
- the third aspect of the present invention provides an intermediate compound, the structure of which is shown in the following formula (V):
- R 3 and R 4 are as defined in the first aspect of the present invention.
- R 3 is -LC(O)NR 5 R 6 , and L is methylene or ethylene;
- R 4 is -O(C 1-6 alkyl
- R 5 and R 6 are each independently selected from hydrogen, C 1-6 alkyl, wherein the alkyl is optionally substituted with 1-2 groups selected from the group consisting of halogen, -O(C 1-6 alkane Group), -NH 2 , -NH (C 1-6 alkyl), -N (C 1-6 alkyl) 2 , five- to seven-membered heterocyclic group, wherein the heterocyclic group contains 1-2 Heteroatoms selected from N, O, S, and the heterocyclic group is optionally substituted with 1-2 groups selected from C 1-6 alkyl; or
- R 5 and R 6 together with the N atom to which they are connected form a five- to seven-membered heterocyclic ring, which optionally contains 1 additional heteroatom selected from N, O, S, and is optionally substituted by 1 -2 substitutions selected from the following groups: halogen, C 1-6 alkyl, -O (C 1-6 alkyl) , -NH 2 , -NH (C 1-6 alkyl), -N (C 1-6 alkyl) 2 .
- R 3 is -LC(O)NR 5 R 6 , and L is methylene;
- R 4 is -O(C 1-6 alkyl
- R 5 and R 6 are each independently selected from hydrogen, C 1-4 alkyl, wherein the alkyl is optionally substituted with 1-2 groups selected from the group consisting of halogen, -O(C 1-2 alkane Group), -NH(C 1-2 alkyl), -N(C 1-2 alkyl) 2 , five- to seven-membered heterocyclic group, wherein the heterocyclic group contains 1-2 selected from N, O, S heteroatoms, and at least one of the heteroatoms is N, and the heterocyclic group is optionally substituted with 1-2 groups selected from C 1-4 alkyl groups; or
- R 5 and R 6 together with the N atom to which they are connected form a five- to seven-membered heterocyclic ring, which optionally contains 1 additional heteroatom selected from N, O, S, and is optionally substituted by 1 -2 substitutions selected from the following groups: halogen, C 1-4 alkyl, -O (C 1-2 alkyl), -NH (C 1-2 alkyl), -N (C 1-2 alkane) Base) 2 .
- R 3 is -LC(O)NR 5 R 6 , and L is methylene;
- R 4 is -O(C 1-6 alkyl
- R 5 and R 6 together with the N atom to which they are connected form a morpholine ring.
- the intermediate compound of formula (V) is compound B1:
- the crystal form I of compound Orin1001 is provided, wherein the X-ray powder diffraction pattern of the crystal form I is about 8.44 ⁇ 0.2°, 13.11 ⁇ 0.2°, 15.70 ⁇ 0.2°, 19.73 ⁇ 0.2°, There are characteristic peaks at the diffraction angles (2 ⁇ ) of 21.00 ⁇ 0.2° and 22.91 ⁇ 0.2°.
- the X-ray powder diffraction pattern of Form I is about 8.44 ⁇ 0.2°, 10.91 ⁇ 0.2°, 10.68 ⁇ 0.2°, 13.11 ⁇ 0.2°, 15.70 ⁇ 0.2°, 17.54 ⁇ 0.2°, 19.73 ⁇ 0.2
- the X-ray powder diffraction pattern of Form I is about 8.44 ⁇ 0.2°, 10.91 ⁇ 0.2°, 10.68 ⁇ 0.2°, 13.11 ⁇ 0.2°, 15.70 ⁇ 0.2°, 16.90 ⁇ 0.2°, 17.54
- the X-ray powder diffraction pattern of the crystal form I has a characteristic peak at the diffraction angle (2 ⁇ ) as shown in Table 1. In another embodiment, the X-ray powder diffraction pattern of Form I is substantially as shown in FIG. 1.
- the crystal form I satisfies at least one of the following (1) to (3):
- thermogravimetric analysis chart is basically shown in Figure 2;
- the starting temperature of the crystalline form I is about 239°C ⁇ 5°C, and the peak temperature is about 242°C ⁇ 5°C.
- the crystal form I is an anhydrate crystal form.
- the X-ray powder diffraction pattern of crystal form I is measured by the following method: X-ray powder diffractometer: Bruker D8 advance X; radiation source: Cu-K ⁇ ; scanning range: 3°(2 ⁇ ) ⁇ 40 °(2 ⁇ ); scanning step: 0.02°(2 ⁇ ); scanning speed: 0.3sec/step.
- thermogravimetric analysis pattern of crystal form I is determined by the following method: TGA thermogravimetric analyzer: TA TGA Q500; temperature range: room temperature to 350°C; scanning rate: 10°C/min; protective gas: nitrogen ; Flow rate: 40mL/min (balance) or 60mL/min (sample).
- the differential scanning calorimetry profile of Form I is determined by the following method: DSC differential scanning calorimetry analyzer: TA DSC Q200; temperature range: 25°C ⁇ 300°C; scanning rate: 10°C /min; Shielding gas: nitrogen; flow rate: 50mL/min.
- the dynamic moisture adsorption profile of crystal form I is determined by the following method: DVS dynamic moisture adsorber: IGASORP; temperature: 25°C; temperature stability: 0.1°C/min; carrier gas: nitrogen; flow rate: 250mL /min; scan: 2; minimum time: 30min; maximum time: 2 hours; waiting limit: 98%; humidity change gradient: adsorption: 0,10,20,30,40,50,60,70,80,90; Desorption: 80,70,60,50,40,30,20,10,0.
- the particle size distribution (PSD) of the crystal form I is measured using Malvern Mastersizer 2000.
- the parameters used can be: pump speed: 2500 rpm; dispersant volume: 800 mL; dispersant: water; dispersion medium: 1% Tween 80.
- the mechanical treatment stability of the crystal form I is determined by the following method: place the crystal form I in a mortar, grind for 2 min and 5 min, respectively, perform XRPD detection, and analyze the ground solid.
- the particle size distribution (PSD) of Form I is shown in Table 2.
- the bulk density of crystal form I is 0.72 g/ml
- the tap density is 0.90 g/ml
- the Carr index is 20%
- the angle of repose is 30.6°.
- the crystal form I of the present invention has excellent stability. For example, after mechanical treatment, the diffraction pattern remains basically unchanged.
- the present invention provides a pharmaceutical composition comprising the crystal form I of the present invention and one or more pharmaceutically acceptable carriers.
- the present invention also provides the crystalline form I of the present invention or the pharmaceutical composition of the present invention when preparing to treat or prevent diseases, disorders or conditions related to unfolded protein response (UPR), or when preparing to treat or prevent
- URR unfolded protein response
- RIDD IRE1-dependent decay
- Another aspect of the present invention also relates to the crystalline form I of the present invention or the pharmaceutical composition of the present invention, for the treatment or prevention of diseases, disorders or conditions associated with unfolded protein responses, or for the treatment or prevention and regulation of IRE1- A disease, disorder, or condition associated with a target of dependent decay.
- Yet another aspect of the present invention also provides methods for treating or preventing diseases, disorders, or conditions associated with unfolded protein responses, or methods for treating or preventing diseases, disorders, or conditions associated with targets that modulate IRE1-dependent decay,
- the method includes administering an effective amount of the crystalline form I of the present invention or the pharmaceutical composition of the present invention to an individual in need, or making a therapeutically effective amount of the crystalline form I of the present invention for the disease, disorder, or condition.
- the pharmaceutical composition of the present invention appears in an individual's body.
- the disease, disorder or condition associated with the unfolded protein response is selected from tumors, diseases related to metabolism, diseases related to immunity, viral infections and cardiovascular diseases.
- the disease, disorder or condition associated with the unfolded protein response is selected from B cell autoimmune diseases, cancer, and viral infections.
- the treatable B-cell autoimmune disease is selected from: Addision's disease, antiphospholipid syndrome, aplastic anemia, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune Hypophysitis, Autoimmune Lymphocytic Proliferative Disease, Autoimmune Myocarditis, Yau Shier Syndrome, Acquired Epidermolysis Bullosa, Giant Cell Arteritis, Goodpasture Syndrome, Grave S disease, Guerlain-Barr syndrome, Hashimoto's thyroiditis, idiopathic thrombocytopenic purpura, IgA nephropathy, myasthenia gravis, pemphigus foliaceous, pemphigus vulgaris, nodular Arteritis, polymyositis/dermatomyositis, rheumatoid arthritis,
- the treatable cancer is a solid tumor.
- the solid tumor is selected from breast tumors, bone tumors, prostate tumors, lung tumors, adrenal tumors (such as adrenocortical tumors), bile duct tumors, bladder tumors, bronchial tumors, nerve tissue tumors (including neurons and Gliomas), gallbladder tumors, stomach tumors, salivary gland tumors, esophageal tumors, small intestine tumors, cervical tumors, colon tumors, rectal tumors, liver tumors, ovarian tumors, pancreatic tumors, pituitary adenomas and secretory adenomas.
- the treatable cancer is a drug-resistant or radiation-resistant solid tumor. In one embodiment, the treatable cancer is a hematological tumor. In a further embodiment, the hematological tumor is lymphoma or leukemia. In another embodiment, the hematological tumor is indeterminate monoclonal gammopathy (MGUS), a precursor of myeloma.
- MGUS monoclonal gammopathy
- the lymphoma is selected from multiple myeloma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma (e.g., cutaneous T-cell lymphoma, such as Sezari syndrome and mycosis fungoides, diffuse Large cell lymphoma, HTLV-1-related T cell lymphoma, nodal peripheral T cell lymphoma, extranodal peripheral T cell lymphoma, central nervous system lymphoma, and AIDS-related lymphoma tumor).
- Hodgkin’s lymphoma e.g., Hodgkin’s lymphoma
- non-Hodgkin’s lymphoma e.g., cutaneous T-cell lymphoma, such as Sezari syndrome and mycosis fungoides
- diffuse Large cell lymphoma HTLV-1-related T cell lymphoma
- nodal peripheral T cell lymphoma nodal peripheral T cell lymphoma
- the leukemia is selected from acute and chronic lymphocytic and myeloid leukemia (e.g., acute lymphocytic or lymphoblastic leukemia, acute myeloid leukemia, acute myeloid leukemia, chronic myeloid leukemia Leukemia, chronic lymphocytic leukemia, T-cell prelymphocytic leukemia, adult T-cell leukemia and hairy cell leukemia).
- a treatable viral infection is an enveloped viral infection that utilizes an unfolded protein response pathway when replicating and forming infectious offspring.
- the treatable viral infection is selected from measles virus, pox virus, Ebola virus (Ebola).
- the treatable viral infection is an infection selected from Epstein Barr virus (EBV), cytomegalovirus (CMV), viruses of the flavivirus genus (for example, Japanese encephalitis virus and West Nile virus) and C Those infections caused by hepatitis B virus (HCV).
- EBV Epstein Barr virus
- CMV cytomegalovirus
- HCV hepatitis B virus
- the disease, disorder, or condition related to the target that modulates IRE1-dependent decay is selected from neurological disorders, disorders involving insulin overproduction, and disorders involving inflammation.
- the neurological disorder is schizophrenia.
- the condition involving insulin overproduction is type II diabetes.
- the condition involving inflammation is selected from the group consisting of glomerulonephritis, various forms of arthritis, multiple sclerosis and inflammatory bowel disease.
- the method of the present invention Compared with the method in the prior art (such as CN103079558 A), the method of the present invention has the advantages of simplicity and efficiency, high atom utilization, and high yield.
- the intermediate 5A2 was prepared according to the method of CN103079558 A, the route is as follows:
- the route includes:
- Step (1) Prepare ethyl acetoacetate compound (compound 2) whose ⁇ -position is substituted by ester alkyl group (compound 2) from ethyl acetoacetate (SM1) and ethyl bromoacetate (SM2), the yield is 80%; 2): Preparation of coumarin compounds (compound 3) whose 3-position is substituted by ester group alkyl, yield 60%; step (3): preparation of compound 4, yield 67%; step (4): pass acid Amine condensation reaction introduces an amide group to prepare compound 5A2.
- step (4) was performed according to the method of CN103079558 A in Example 62, and the crude compound 5A2 was obtained, and the yield was 43%.
- the total yield of the above steps (1) to (4) is about 13.8%, and the total yield of the above steps (2) to (4) is about 17.3%.
- Steps (2) to (4) are three-step continuous linear reactions carried out in a linear synthesis mode.
- Step (2) constructs coumarin with compound 1 through a ring-closure reaction.
- step (3) and step (4) further introduce an amide group on the 3-position substituent to obtain compound 5A2.
- the ester group needs to be introduced into compound 3 first, and then removed and converted into an amide group.
- the steps are cumbersome, the atom economy is not good, and the yield is low.
- the acetyl whose ⁇ -position is substituted by amidoalkyl is first prepared through two steps. Alkyl acetate (for example, see the method for preparing the compound of formula (V) or the preparation of intermediate compound B1, or for example the method shown in Example 1), and then directly construct the coumarin core through a ring closure step with compound 1 .
- the total number of the above steps is 3.
- the preparation method of the present invention realizes a convergence synthesis (convergent synthesis), reduces the steps of continuous reaction, and is beneficial to further improving production efficiency.
- the inventors unexpectedly discovered that the present invention utilizes a ring-closure reaction between an acetoacetate alkyl ester compound substituted by an amidoalkyl group at the ⁇ -position and a substituted phenol compound to construct a coumarin core, which is to achieve convergent synthesis, reduce reaction steps, The key to improving the total reaction yield, atomic economy and production efficiency.
- the amide group is introduced by the acyl halide compound of formula (II) (or compound D1) having a bifunctional group, and the ester group is introduced into CN103079558 A and then hydrolyzed, and then the acid amine condensation is carried out. Compared with, obviously have higher atomic utilization rate.
- the preparation method of the present invention also realizes a higher total yield, which is beneficial to industrialized production.
- the total yield of Example 1 to Example 2 is about 46.6%.
- the method for preparing coumarin compounds whose 3-position is substituted by an amidoalkyl group of the present invention has the following advantages: optimizing the introduction time of the amide group, first preparing the 1,3-dicarbonyl compound containing the amide substitution, It is then used for ring closure to efficiently construct the coumarin core structure and side chains containing amide groups in a simple route, with high atom utilization and high yield, which is conducive to industrial production.
- a convergent synthesis route is constructed, which shortens the steps of continuous reaction, which is beneficial to further improve production efficiency.
- the crystal form I of Orin1001 of the present invention has high purity, high stability, good operability, simple preparation process, and can be applied to large-scale production.
- X-ray powder diffractometer Bruker D8 advance X
- the radiation source is Cu-K ⁇
- the test scan range is 3°(2 ⁇ ) ⁇ 40°(2 ⁇ )
- the scan step size is 0.02°(2 ⁇ )
- the scan speed is 0.3 sec/step.
- TGA thermogravimetric analyzer TA TGA Q500, the temperature range is from room temperature to 350°C, the scanning rate is 10°C/min, the protective gas is nitrogen, and the flow rate is 40mL/min (balance) or 60mL/min (sample).
- DSC Differential Scanning Calorimetry Analyzer TA DSC Q200, the temperature range is 25°C ⁇ 300°C, the scanning rate is 10°C/min, the protective gas is nitrogen, and the flow rate is 50mL/min.
- DVS dynamic moisture adsorber IGASORP, temperature is 25°C, temperature stability: 0.1°C/min, carrier gas is nitrogen, flow rate is 250mL/min, scan: 2, minimum time is 30min, maximum time is 2 hours, waiting for the upper limit 98%, humidity gradient: adsorption: 0,10,20,30,40,50,60,70,80,90; desorption: 80,70,60,50,40,30,20,10,0 .
- HPLC Reaction monitoring: Waters Acquity Arc liquid chromatography system or equivalent equipment; Column: ZORBA ⁇ Eclipse ⁇ DB C18, 4.6 ⁇ 150mm, 3.5 ⁇ m, or the same type of chromatographic column; Mobile phase A: 0.05% trifluoroacetic acid Aqueous solution; mobile phase B: 0.05% trifluoroacetic acid acetonitrile solution; concentration gradient running time: 20 minutes.
- HPLC Purity determination: Waters Acquity Arc liquid chromatography system or equivalent equipment; Chromatographic column: Eclipse ⁇ DB C18, 4.6 ⁇ 150mm, 3.5 ⁇ m, or the same type of chromatographic column; Column temperature: 30°C; Detection wavelength: 210nm; Mobile phase A: 0.05% trifluoroacetic acid aqueous solution; mobile phase B: 0.05% trifluoroacetic acid acetonitrile solution; concentration gradient running time: 20 minutes.
- LC-MS use Shimadzu LCMS 2010 (chromatographic column: sepax ODS 50 ⁇ 2.0mm, 5 ⁇ m), or Agilent 1200 HPLC, 1956 MSD (chromatographic column: Shim-pack XR-ODS 30 ⁇ 3.0mm, 2.2 ⁇ m), or NB -PDM-LCMS-004 (Column: Agilent SB-C18 4.6x50mm 1.8 ⁇ m, or poroshell SB-C 18 2.7um 3.0*50mm, SN: USCFE02201), ionization method ES(+).
- halogenated acetyl halide (compound D1) is reacted with amine (morpholine) to prepare ⁇ -halogenated amide (compound C1), and then it is reacted with ethyl acetoacetate to prepare ⁇ -position amide alkane Group-substituted ethyl acetoacetate compound (Intermediate B1).
- the intermediate B1 undergoes a condensation reaction with a substituted phenol compound (compound 1), and the ring is closed to obtain the coumarin compound 5A2 whose 3-position is substituted by an amidoalkyl group, which introduces the aldehyde by reacting with hexamethylenetetramine (HMTA) Base to obtain the target compound Orin1001.
- HMTA hexamethylenetetramine
- Method A uses bromoacetyl bromide to prepare intermediate B1:
- Intermediate C1-1 can be prepared by referring to the method disclosed in Example A9 Step 1 of International Patent Application WO1999032436, or prepared according to Method 1 or Method 2 below.
- bromoacetyl bromide (D1-1, 250g, 1.00eq.) and dichloromethane (3.75L) were added to a 5L four-neck flask, and the temperature was reduced to 5°C with a brine bath.
- Add morpholine (216g, 2.00eq.) dropwise and control the temperature to 0-10°C. After the addition is completed, control the reaction temperature to be ⁇ 10°C, and stir for 30 minutes. Remove the salt water bath and react at room temperature for 2 hours. TLC detection showed that the bromoacetyl bromide reaction was complete. The temperature of the system was reduced to ⁇ 10°C, and saturated aqueous NH 4 Cl (1.25L) was added dropwise.
- THF (4.45kg, 5.0L) was added to intermediate C1-1 (4.93kg, 1.00eq.), stirred to obtain a clear THF solution of intermediate C1-1, and cooled to 0-5°C for use.
- THF 17.8kg, 20.0L
- NaH 60%, 0.845kg, 1.10eq.
- ethyl acetoacetate 2.50kg, 1.00eq.
- 0 ⁇ 5°C in advance into the kettle, stir at 0 ⁇ 5°C for at least 0.5 hours, and then add the above prepared intermediate at 0 ⁇ 5°C THF solution of C1-1.
- reaction was continued to stir at 0-5°C for at least 2 hours. Sampling was sent to HPLC to monitor the reaction until the peak area of intermediate C1-1 was ⁇ 5.0%.
- a saturated aqueous NH 4 Cl solution (35.0 L) was added at 0-5°C, and the mixture was allowed to stand to separate layers.
- the aqueous phase was extracted with ethyl acetate (25.0L), the organic layers were combined, and concentrated under reduced pressure at about 45°C to 5.0 ⁇ 1.0V, then water (6.5L) was added, and the mixture was stirred for 15 minutes. The mixture was allowed to stand and separate into layers, and the organic layer was concentrated under reduced pressure at 45° C. until no obvious fraction was dripped out.
- Method B uses chloroacetyl chloride to prepare intermediate B1:
- Intermediate C1-2 can be prepared by referring to the method disclosed in US Pat. No. 5,753,660 A, Part A, or according to the following method.
- the mixture was centrifuged, and the solid obtained by centrifugation was rinsed with water (8.0 L) and acetonitrile (5.5 L x 2) respectively to obtain a wet solid.
- the reactor was replaced with nitrogen 3 times.
- the XRPD pattern of crystal form I is basically shown in Figure 1.
- the 2 ⁇ data table is shown in Table 1.
- thermogravimetric analysis when heated to 200°C, there is a weight loss gradient of about 0.017%, and the thermogravimetric analysis chart is basically shown in Figure 2. It can be seen from Figure 2 that Orin1001 crystal form I is anhydrous.
- the crystal form I gained 0.34% in weight after equilibrium at 90% relative humidity, which only slightly induced moisture, and the crystal form did not change after the DVS measurement.
- the DVS detection result is basically shown in Figure 4, and the XRPD comparison chart before and after the DVS detection is basically shown in Figure 5. It can be seen from Figures 4 and 5 that the Orin1001 crystal form I is slightly hygroscopic.
- Trifluoroacetic acid (230.40kg, 150.0L, 20.0V) was added to the reaction kettle, and the temperature was lowered to 0-10°C. Control the temperature below 10°C, add hexamethylenetetramine (HMTA, 23.44kg, 7.50eq.) and intermediate 5A2 (7.44kg, 1.00eq.). Adjust the temperature to 80 ⁇ 5°C and stir for at least 40 hours. Sampling was sent to HPLC to monitor the reaction until the peak area of intermediate 5A2 was ⁇ 5.0%. The reaction solution was concentrated under reduced pressure to about 120L at a temperature below 70°C. The temperature was lowered to 0-10°C, and purified water (200.0L) and Orin1001 seed crystals (1.00wt%) were added.
- the crystal form I was tested for particle size distribution (PSD) and mechanical treatment stability. The results are as follows.
- Form I is a granular crystal, and its particle size is 50-100 ⁇ m when observed under a microscope (Nikon Eclipse LV100POL).
- PSD particle size distribution
- the bulk density of crystal form I is 0.72g/ml, the tap density is 0.90g/ml, the Carr index is 20%, the angle of repose is 30.6°, and the fluidity is very good.
- the powder with good fluidity is not easy to fly, the adsorption is small, the viscosity is also small, and it has the convenience of industrial application.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
2θ角(°) | 强度% | 2θ角(°) | 强度% |
8.44 | 27.6 | 26.27 | 81 |
10.68 | 15.1 | 27.28 | 13.2 |
10.91 | 17.2 | 28.06 | 7.1 |
13.11 | 23.1 | 28.64 | 30.6 |
15.12 | 13.4 | 29.50 | 8.8 |
15.70 | 87.7 | 29.79 | 8 |
16.19 | 12.3 | 30.58 | 17.9 |
16.9 | 36.6 | 31.32 | 9.3 |
17.30 | 19.8 | 31.67 | 17.9 |
17.54 | 46 | 32.23 | 9.5 |
18.15 | 7.5 | 32.70 | 6.3 |
19.73 | 87.1 | 33.20 | 6.9 |
20.14 | 30.8 | 33.62 | 7 |
21.00 | 76.5 | 34.05 | 10.1 |
21.34 | 31.7 | 36.21 | 4.3 |
22.91 | 100 | 36.73 | 6.2 |
23.49 | 9.6 | 37.58 | 8.3 |
23.86 | 7.3 | 37.98 | 8.1 |
24.61 | 8.3 | 38.63 | 8.5 |
25.33 | 17.1 | 39.67 | 6.1 |
25.96 | 25.8 | - | - |
D(0.1) | D(0.5) | D(0.9) |
67.1μm | 115.5μm | 206.4μm |
D(0.1) | D(0.5) | D(0.9) |
67.1μm | 115.5μm | 206.4μm |
Claims (25)
- 一种制备式(VII)的化合物的方法,包括步骤(A):使式(VI)的化合物与式(V)的化合物反应,以制备式(VII)化合物其中R 1和R 2各自独立地选自氢、卤素和-O(C 1-8烷基),其中所述烷基任选地被1-2个-选自以下的基团取代:卤素、被1-2个羟基取代的C 1-8烷基、-O(C 1-8烷基);R 3为-L-C(O)NR 5R 6,L为C 1-3亚烷基;R 4为-O(C 1-6烷基);R 5和R 6各自独立地选自氢、C 1-8烷基、C 3-10环烃基,其中所述烷基、环烃基任选地被1-2个选自以下的基团取代:卤素、-O(C 1-8烷基)、-NH 2、-NH(C 1-8烷基)、-N(C 1-8烷基) 2、五元至七元杂环基,其中所述杂环基含有1-2个选自N、O、S的杂原子,并且所述杂环基任选地被1-2个选自C 1-8烷基的基团取代;或者R 5和R 6连同与其相连的N原子一起形成五元至七元杂环基,所述杂环基任选地含有1个选自N、O、S的额外的杂原子,并且任选地被1-2个选自以下的基团取代:卤素、C 1-8烷基、-O(C 1-8烷基)、-NH 2、-NH(C 1-8烷基)、-N(C 1-8烷基) 2。
- 权利要求1的方法,其中R 4为-O(C 1-4烷基);优选-O(C 1-2烷基);更优选乙氧基。
- 权利要求1的方法,其中L为亚甲基或亚乙基,优选亚甲基。
- 权利要求1的方法,其中R 5和R 6各自独立地选自氢、C 1-6烷基,其中所述烷基任选地被1-2个选自以下的基团取代:卤素、-O(C 1-6烷基)、-NH 2、-NH(C 1-6烷基)、-N(C 1-6烷基) 2、五元至七元杂环基,其中所述杂环基含有1-2个选自N、O、S的杂原子,并且 所述杂环基任选地被1-2个选自C 1-6烷基的基团取代;或者R 5和R 6连同与其相连的N原子一起形成五元至七元杂环基,所述杂环基任选地含有1个选自N、O、S的额外的杂原子,并且任选地被1-2个选自以下的基团取代:卤素、C 1-6烷基、-O(C 1-6烷基)、-NH 2、-NH(C 1-6烷基)、-N(C 1-6烷基) 2;优选地,R 5和R 6各自独立地选自氢、C 1-4烷基,其中所述烷基任选地被1-2个选自以下的基团取代:卤素、-O(C 1-2烷基)、-NH(C 1-2烷基)、-N(C 1-2烷基) 2、五元至七元杂环基,其中所述杂环基含有1-2个选自N、O、S的杂原子,并且所述杂原子中的至少一个为N,并且所述杂环基任选地被1-2个选自C 1-4烷基的基团取代;或者R 5和R 6连同与其相连的N原子一起形成五元至七元杂环基,所述杂环基任选地含有1个选自N、O、S的额外的杂原子,并且任选地被1-2个选自以下的基团取代:卤素、C 1-4烷基、-O(C 1-2烷基)、-NH(C 1-2烷基)、-N(C 1-2烷基) 2;更优选地,R 5和R 6各自独立地选自氢、C 1-2烷基,其中所述烷基任选地被1-2个选自以下的基团取代:甲氧基、二甲氨基、吗啉基、哌啶基或哌嗪基,所述吗啉基、哌啶基或哌嗪基任选地被甲基取代;或者R 5和R 6连同与其相连的N原子一起形成吗啉基、哌啶基或哌嗪基,所述吗啉基、哌啶基或哌嗪基任选地被甲基取代;进一步优选地,R 5和R 6各自独立地选自氢、C 1-2烷基,其中所述烷基被吗啉基取代;或者R 5和R 6连同与其相连的N原子一起形成吗啉基。
- 权利要求1-6中任一项的方法,其中步骤(A)在酸性条件下进行,和/或反应温度为-20℃至70℃,优选-5℃至60℃,更优选20℃至50℃。
- 权利要求1的方法,在步骤(A)之前还包括:步骤(a):使式(II)化合物与胺化合物HNR 5R 6发生缩合反应,以制备式(III)化合物其中X为卤素,优选Cl或Br,更优选Br;L、R 3、R 5和R 6如权利要求1所定义;优选地,反应在有机溶剂中进行;更优选地,有机溶剂为中性非质子性溶剂;进一步优选地,有机溶剂选自烃类溶剂、醚类溶剂、二取代酰胺类溶剂、酯类溶剂及其组合;更优选地,所述烃类溶剂选自二氯甲烷、甲苯、二甲苯及其组合;和/或所述醚类溶剂选自四氢呋喃、甲基四氢呋喃、二氧六环、乙二醇二甲醚,甲基叔丁基醚及其组合;和/或所述二取代酰胺类溶剂选自N,N-二甲基甲酰胺、N,N-二乙基甲酰胺、N,N-二甲基乙酰胺、N,N-二乙基乙酰胺、N-甲基吡咯烷酮及其组合;和/或所述酯类溶剂选自乙酸乙酯、乙酸异丙酯、乙酸丁酯及其组合;和/或反应温度为-10℃至60℃,优选0℃至室温,更优选0℃至10℃;步骤(b):使式(III)化合物与式(IV)化合物反应以制备式(V)化合物其中X为卤素,优选Cl或Br,更优选Br;R 4如权利要求1所定义;优选地,反应在碱的存在下进行,所述碱为有机碱或无机碱;更优选地,所述有机碱选自NaNH 2、醇钠、K-HMDS、Li-HMDS;和/或所述无机碱选自碳酸盐和金属氢化物;优选地,所述碳酸盐选自碳酸钠、碳酸钾、碳酸锂;更优选碳酸钠或碳酸钾,特别优选碳酸钾;和/或所述金属氢化物选自NaH、KH、LiH、CaH 2,特别优选NaH;优选地,反应在有机溶剂中进行;优选地,所述有机溶剂为中性非质子性溶剂;进一步优选地,有机溶剂选自烃类溶剂、醚类溶剂、二取代酰胺类溶剂及其组合;更优选地,所述烃类溶剂选自二氯甲烷、甲苯、二甲苯及其组合;和/或所述醚类溶剂选自四氢呋喃、甲基四氢呋喃、二氧六环、乙二醇二甲醚,甲基叔丁基醚及其组合;和/或所述二取代酰胺类溶剂选自N,N-二甲基甲酰胺、N,N-二乙基甲酰胺、N,N-二甲基乙酰胺、N,N-二乙基乙酰胺、N-甲基吡咯烷酮及其组合;和/或反应温度为-20至100℃,优选-20至80℃,更优选-10至60℃。
- 权利要求13的晶型I,其中所述晶型I的X射线粉末衍射图谱在约8.44±0.2°、10.91±0.2°、10.68±0.2°、13.11±0.2°、15.70±0.2°、17.54±0.2°、19.73±0.2°、21.00±0.2°、22.91±0.2°、26.27±0.2°的衍射角(2θ)处有特征峰,优选地在约8.44±0.2°、10.91±0.2°、10.68±0.2°、13.11±0.2°、15.70±0.2°、16.90±0.2°、17.54±0.2°、19.73±0.2°、21.00±0.2°、22.91±0.2°、26.27±0.2°、28.64±0.2°的衍射角(2θ)处有特征峰。
- 权利要求13或14的晶型I,其中所述晶型I的X射线粉末衍射图谱在如表1所示的衍射角(2θ)处有特征峰。
- 权利要求13-15中任一项的晶型I,其中所述晶型I的X射线粉末衍射图谱基本上如图1所示。
- 权利要求13-16中任一项的晶型I,其中所述晶型I满足以下(1)至(3)中的至少一个:(1)热重分析图谱基本上如图2所示;(2)差示扫描量热分析图谱基本上如图3所示;(3)动态水分吸附图谱基本上如图4所示。
- 权利要求13-17中任一项的晶型I,其中当用DSC进行表征时,所述晶型I的起始温度约为239℃±5℃,峰值温度约为242℃±5℃。
- 权利要求13-18中任一项的晶型I,其为无水物晶型。
- 一种制备权利要求13-19中任一项的晶型I的方法,包括:步骤i:在步骤(B)反应结束后,浓缩反应液,加入水和式(I)化合物晶种诱导析晶;步骤ii:分离步骤i得到的粗产品,与合适的溶剂在加热条件下搅拌,然后降温,分离得到结晶态的式(I)化合物。
- 权利要求20的方法,其中步骤ii分离粗产品之后、与合适的溶剂在加热条件下搅拌之前,还包括用合适的溶剂淋洗粗产品的步骤;和/或步骤ii分离得到结晶态的式(I)化合物之后,还包括用合适的溶剂淋洗、干燥的步骤;和/或步骤ii所述合适的溶剂选自腈类溶剂或腈类溶剂与水的混合溶剂;优选地,腈类溶剂选自乙腈、苯腈、苯乙腈或其组合,优选乙腈;和/或步骤ii所述加热温度优选40-80℃,更优选50-70℃;和/或步骤ii的加热时间至少2h,优选至少4h,更优选至少8小时。
- 一种药物组合物,其包含权利要求13-19中任一项的晶型I以及一种或多种药学上可接受的载体。
- 权利要求13-19中任一项的晶型I或者权利要求22的药物组合物在制备治疗或预防与未折叠蛋白质应答相关或者与调节IRE1-依赖性衰解的靶标相关的疾病、病症或病况的药物中的应用。
- 权利要求23的应用,其中所述与未折叠蛋白质应答相关的疾病、病症或病况选自B细胞自身免疫疾病、癌症和病毒感染;优选地,所述B-细胞自身免疫疾病选自:艾迪生病(Addision’s disease)、抗磷脂综合征、再生障碍性贫血、自体免疫溶血性贫血、自身免疫性肝炎、自身免疫性垂体炎、自身免疫性淋巴细胞增生性疾病、自身免疫性心肌炎、丘-施二氏综合征、后天性大疱性表皮松解、巨细胞性动脉炎、古德帕斯彻综合征、格雷夫斯病、格-巴二氏综合征、桥本甲状腺炎、特发性血小板减少性紫癜、IgA肾病、重症肌无力、落叶型天疱疮、寻常天疱疮、结节性多动脉炎、多发性肌炎/皮肌炎、类风湿性关节炎、硬皮病、斯耶格仑综合征、全身性红斑狼疮、高安氏动脉炎和韦格纳肉芽肿病;和/或所述癌症为选自以下的实体瘤:乳腺肿瘤、骨肿瘤、前列腺肿瘤、肺肿瘤、肾上腺肿瘤、胆管肿瘤、膀胱肿瘤、支气管肿瘤、神经组织肿瘤、胆囊肿瘤、胃肿瘤、唾液腺肿瘤、食道肿瘤、小肠肿瘤、子宫颈肿瘤、结肠肿瘤、直肠肿瘤、肝肿瘤、卵巢肿瘤、胰腺肿瘤、垂体腺瘤和分泌腺瘤;和/或所述癌症为药物-耐受性或辐射-耐受性实体瘤;和/或所述癌症为选自以下的血液肿瘤:淋巴瘤、白血病和未定性单克隆丙种球蛋白病(MGUS);优选地,所述淋巴瘤选自多发性骨髓瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤,和/或白血病选自急性和慢性的淋巴细胞性和髓细胞性白血病;和/或所述病毒感染为被膜病毒感染;优选地,病毒感染为在复制和形成感染性后代时利用未折叠蛋白质应答途径的被膜病毒感染;更优选地,病毒感染选自麻疹病毒、痘病毒、埃博拉病毒(Ebola)、Epstein Barr病毒(EBV)、巨细胞病毒(CMV)、黄病毒属的病毒、和 丙型肝炎病毒(HCV)所致的感染;其中所述黄病毒属的病毒优选为日本脑炎病毒或西尼罗病毒。
- 权利要求23的应用,其中所述与调节IRE1-依赖性衰解的靶标相关的疾病、病症或病况选自神经病症、涉及胰岛素超量产生的病症和涉及炎症的病症;优选地,所述神经病症为精神分裂症,所述涉及胰岛素超量产生的病症为II型糖尿病,所述涉及炎症的病症选自肾小球性肾炎、各种形式的关节炎、多发性硬化和炎性肠病。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2022008241A MX2022008241A (es) | 2019-12-31 | 2020-12-30 | Un método para preparar compuestos de cumarina sustituidos con amidoalquilo en la posición 3, los productos e intermedios relacionados con los mismos. |
CA3163528A CA3163528A1 (en) | 2019-12-31 | 2020-12-30 | A method for preparing coumarin compounds substituted by amidoalkyl at 3-position, the products and related intermediates thereof |
CN202080091526.9A CN114929692A (zh) | 2019-12-31 | 2020-12-30 | 一种制备3-位被酰胺基烷基取代的香豆素类化合物的方法及其产物和相关中间体 |
US17/758,267 US20230067666A1 (en) | 2019-12-31 | 2020-12-30 | Method for preparing coumarin compounds substituted by amidoalkyl at 3-position, the products and related intermediates thereof |
JP2022540994A JP2023509180A (ja) | 2019-12-31 | 2020-12-30 | 3位がアミドアルキル基で置換されたクマリン系化合物の製造方法、その生成物及び関連中間体 |
EP20910574.1A EP4089090A4 (en) | 2019-12-31 | 2020-12-30 | PROCESS FOR PREPARING COUMARIN COMPOUND, POSITION 3 OF WHICH IS SUBSTITUTED BY AN AMIDOALKYL, AND ASSOCIATED PRODUCTS AND INTERMEDIATES THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911422365.2A CN113121484A (zh) | 2019-12-31 | 2019-12-31 | 一种制备3-位被酰胺基烷基取代的香豆素类化合物的方法及其产物和相关中间体 |
CN201911422365.2 | 2019-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021136333A1 true WO2021136333A1 (zh) | 2021-07-08 |
Family
ID=76686524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/141203 WO2021136333A1 (zh) | 2019-12-31 | 2020-12-30 | 一种制备3-位被酰胺基烷基取代的香豆素类化合物的方法及其产物和相关中间体 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230067666A1 (zh) |
EP (1) | EP4089090A4 (zh) |
JP (1) | JP2023509180A (zh) |
CN (2) | CN113121484A (zh) |
CA (1) | CA3163528A1 (zh) |
MX (1) | MX2022008241A (zh) |
WO (1) | WO2021136333A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5693868A (en) * | 1995-10-31 | 1997-12-02 | Takasago International Corporation | Method for producing optically active diphosphine compounds |
US5753660A (en) | 1995-11-15 | 1998-05-19 | G. D. Searle & Co. | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
WO1999032436A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
CN102666496A (zh) * | 2010-01-21 | 2012-09-12 | 保宁制药株式会社 | 2-(2-正丁基-4-羟基-6-甲基-嘧啶-5-基)-n,n-二甲基乙酰胺的新制备方法 |
CN103079558A (zh) | 2010-04-05 | 2013-05-01 | 满康德股份有限公司 | IRE-1α抑制剂 |
CN107973784A (zh) | 2017-11-16 | 2018-05-01 | 珠海市海瑞德生物科技有限公司 | 一种非马沙坦的合成方法 |
-
2019
- 2019-12-31 CN CN201911422365.2A patent/CN113121484A/zh active Pending
-
2020
- 2020-12-30 CA CA3163528A patent/CA3163528A1/en active Pending
- 2020-12-30 WO PCT/CN2020/141203 patent/WO2021136333A1/zh unknown
- 2020-12-30 EP EP20910574.1A patent/EP4089090A4/en active Pending
- 2020-12-30 CN CN202080091526.9A patent/CN114929692A/zh active Pending
- 2020-12-30 US US17/758,267 patent/US20230067666A1/en active Pending
- 2020-12-30 JP JP2022540994A patent/JP2023509180A/ja active Pending
- 2020-12-30 MX MX2022008241A patent/MX2022008241A/es unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5693868A (en) * | 1995-10-31 | 1997-12-02 | Takasago International Corporation | Method for producing optically active diphosphine compounds |
US5753660A (en) | 1995-11-15 | 1998-05-19 | G. D. Searle & Co. | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
WO1999032436A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
CN102666496A (zh) * | 2010-01-21 | 2012-09-12 | 保宁制药株式会社 | 2-(2-正丁基-4-羟基-6-甲基-嘧啶-5-基)-n,n-二甲基乙酰胺的新制备方法 |
CN103079558A (zh) | 2010-04-05 | 2013-05-01 | 满康德股份有限公司 | IRE-1α抑制剂 |
CN107973784A (zh) | 2017-11-16 | 2018-05-01 | 珠海市海瑞德生物科技有限公司 | 一种非马沙坦的合成方法 |
Non-Patent Citations (2)
Title |
---|
MOON MALCOLM W.: "Synthesis and Acylation of Pyrrolinones", JOURNAL OF ORGANIC CHEMISTRY, vol. 42, no. 13, 1 January 1977 (1977-01-01), pages 2219 - 2223, XP055826461 * |
See also references of EP4089090A4 |
Also Published As
Publication number | Publication date |
---|---|
CN114929692A (zh) | 2022-08-19 |
EP4089090A1 (en) | 2022-11-16 |
MX2022008241A (es) | 2022-10-07 |
JP2023509180A (ja) | 2023-03-07 |
CN113121484A (zh) | 2021-07-16 |
CA3163528A1 (en) | 2021-07-08 |
US20230067666A1 (en) | 2023-03-02 |
EP4089090A4 (en) | 2024-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3442977B1 (en) | Inhibitors of activin receptor-like kinase | |
CA2965981C (en) | Substituted chromanes and method of use | |
WO2023001141A1 (en) | Kras g12d inhibitors and uses thereof | |
JP2011529952A (ja) | ジアザインドール誘導体およびc−JunN末端キナーゼの阻害におけるそれらの使用 | |
EA025881B1 (ru) | Макроциклические ингибиторы flt3-киназы | |
JP6986032B2 (ja) | Jak阻害剤としてのピロロピリミジン化合物の結晶 | |
CN118613478A (zh) | Kif18a抑制剂 | |
CN116802179A (zh) | Bcl-2抑制剂 | |
CN118215657A (zh) | Kif18a抑制剂 | |
CN115594664A (zh) | 一类螺环衍生物作为kif18a抑制剂 | |
CN109721600A (zh) | 一类含氮稠环化合物及其制备方法和用途 | |
JP2016145212A (ja) | Cddoエチルエステルの多形体及びその用途 | |
EP3990445A1 (en) | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | |
CN111094314B (zh) | 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用 | |
JP2014534208A5 (zh) | ||
JP2022500476A (ja) | 環状ジヌクレオチド類似体、その医薬組成物及び使用 | |
CN107556366A (zh) | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 | |
WO2021136333A1 (zh) | 一种制备3-位被酰胺基烷基取代的香豆素类化合物的方法及其产物和相关中间体 | |
CN111225907A (zh) | 制备苯并噻吩-2基硼酸/硼酸盐的方法 | |
CN115867542A (zh) | 新型苯并咪唑化合物 | |
EA032872B1 (ru) | Макроциклические ингибиторы rip2-киназы | |
EP3805212A1 (en) | 3-oxazolinone compound, preparation method therefor and pharmaceutical application thereof | |
CN117957232A (zh) | 氮杂吲唑大环化合物及其用途 | |
CN113666863B (zh) | 可用作RORγ调节剂的联芳基类化合物 | |
CN113666853B (zh) | 可用作RORγ调节剂的联芳基类化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20910574 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022540994 Country of ref document: JP Kind code of ref document: A Ref document number: 3163528 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020910574 Country of ref document: EP Effective date: 20220801 |